Conmed Corp
F:EC8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Conmed Corp
F:EC8
|
US |
|
N
|
Nov Inc
BMV:NOV
|
US |
|
S
|
Sime Darby Plantation Bhd
KLSE:SIMEPLT
|
MY |
|
M
|
Mitsubishi Estate Co Ltd
DUS:MES
|
JP |
|
Starbucks Corp
NASDAQ:SBUX
|
US |
|
Physicians Realty Trust
F:42O
|
US |
|
Y
|
Yellow Cake PLC
F:0LZ
|
JE |
Conmed Corp
CONMED makes medical devices that doctors and hospitals use in surgery and other procedures. Its products include tools for minimally invasive surgery, orthopedics, and patient care in the operating room. The company sells to hospitals, ambulatory surgery centers, and medical groups that need reliable instruments and disposable supplies for everyday procedures. The business makes money by selling capital equipment, single-use instruments, and replacement parts and accessories. Some products are sold through direct sales teams and some through distributors, depending on the market. A large part of the appeal of this model is that hospitals often keep buying consumable items after they adopt the equipment, which can make the relationship with customers longer lasting. CONMED sits in the middle of the surgical supply chain: it does not run hospitals or perform procedures, but it supplies the tools surgeons need to do them. That makes it different from companies that sell broad medical software or general healthcare products. Its business depends on clinical adoption, product reliability, and ongoing demand from procedure-based care.
CONMED makes medical devices that doctors and hospitals use in surgery and other procedures. Its products include tools for minimally invasive surgery, orthopedics, and patient care in the operating room. The company sells to hospitals, ambulatory surgery centers, and medical groups that need reliable instruments and disposable supplies for everyday procedures.
The business makes money by selling capital equipment, single-use instruments, and replacement parts and accessories. Some products are sold through direct sales teams and some through distributors, depending on the market. A large part of the appeal of this model is that hospitals often keep buying consumable items after they adopt the equipment, which can make the relationship with customers longer lasting.
CONMED sits in the middle of the surgical supply chain: it does not run hospitals or perform procedures, but it supplies the tools surgeons need to do them. That makes it different from companies that sell broad medical software or general healthcare products. Its business depends on clinical adoption, product reliability, and ongoing demand from procedure-based care.
Top line: CONMED reported Q1 sales of $317 million, with organic sales up 2.1% as the GI portfolio exit continued to weigh on reported results.
Guidance raised: Management lifted 2026 organic growth guidance to 5.0% to 6.5% from 4.5% to 6.0% and raised reported revenue guidance to $1.35 billion to $1.375 billion.
Margin strength: Adjusted gross margin came in at 57.4%, up 100 basis points year over year and at the top end of the company’s full-year margin improvement range.
Strategic reset: CONMED completed agreements to divest its remaining GI products, sharpening focus on AirSeal, Buffalo Filter and BioBrace.
Debt plan: The company expects to refinance debt in Q2 with bank debt rather than new convertible notes, which should add at least $0.10 of adjusted EPS headwind, but full-year EPS guidance stayed unchanged.
Growth drivers: Management said orthopedic recovery, AirSeal, and smoke evacuation are all showing better momentum, with BioBrace continuing to gain surgeon adoption.
